(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 10 July 2003 (10.07.2003)

PCT

(10) International Publication Number WO 03/055456 A1

(51) International Patent Classification?: A61K 7/075, 7/42, 7/48

(21) International Application Number: PCT/US02/41126

(22) International Filing Date:

20 December 2002 (20.12.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/341,845 21 December 2001 (21.12.2001) US 60/369,216 1 April 2002 (01.04.2002) US

- (71) Applicant: RHODIA INC. [US/US]; CN 7500, 259 Prospect Plains Road, Cranbury, NJ 08512 (US).
- (72) Inventors: FRANTZ, Seren; 1241 Neshaminy Valley Dr., Bensalem, PA 19020 (US). COTRELL, Phillip, L.; 22 Hampshire Court, New Egypt, NJ 08533 (US). WARBURTON, Stewart, A.; 6 Greenfield Drive North, West Windsor, NJ 08550 (US).
- (74) Agents: BREW, Michael, R. et al.; Dilworth & Barrese, LLP, 333 Earle Ovington Blvd., Uniondale, NY 11553 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



3/055456 A1

(54) Title: STABLE SURFACTANT COMPOSITIONS FOR SUSPENDING COMPONENTS

(57) Abstract: A free-flowing surfactant composition comprising at least one anionic surface-active agent, an alkanolamide, an electrolyte, and water is described. In particular, the composition is a surfactant composition that has free-flowing non-Newtonian shear thinning properties and the ability to suspend components and is stable under at least one freeze/thaw cycle.

STABLE SURFACTANT COMPOSITIONS FOR SUSPENDING COMPONENTS

BACKGROUND OF THE INVENTION

This application claims the benefit under 35 U.S.C. § 119(e) of earlier filed and copending U.S. Provisional Application No. 60/341,845 filed December 21, 2001 and U.S.

Provisional Application No. 60/369,216 filed April 1, 2002, the contents of each of which are incorporated by reference herein.

1. Technical Field

10

15

This invention relates to aqueous free-flowing compositions. In particular, the invention relates to surfactant compositions that have free-flowing non-Newtonian shear thinning properties and the ability to suspend components.

2. Background of Related Art

It has been documented that free-flowing non-Newtonian shear thinning personal care preparations, comprised of well defined surfactant mixtures, are capable of suspending water-insoluble particles or partially insoluble components, such as vegetable oils, mineral oils, silicone oils, solid particles, abrasives, and similar articles. Examples of such preparations can be found in U.S. Patent No. 5,556,628 and U.S. Patent No. 5,965,500, each of which are incorporated by reference herein to the extent they are not inconsistent with this application. These systems provide a means to include otherwise difficult to incorporate components in surfactant mixtures resulting in cosmetic preparations with multi-functional benefits including, in some cases, cleansing, moisturizing, improved skin feel, exfoliation/abrasion, novel appearance, or a combination of these benefits.

The rheological behavior of all surfactant solutions, including liquid personal care solutions, is believed to be dependent on their microstructure, i.e., the shape and concentration of micelles or other self-assembled structures in solutions.

Micelles are not necessarily spherical and may, for example, exist as cylindrical or discoidal micelles. At higher concentrations more ordered liquid crystal phases such as lamellar phases, hexagonal phases or cubic phases may form. Surfactants can take on organized phases above the critical micelle concentration or CMC. (The CMC is defined as the concentration of a surfactant at which it begins to form micelles in solution.) The rheology of the phase is very important when considering the usefulness of a surfactant system.

5

10

15

20

25

The rheology of surfactant systems can be described in terms of Newtonian and non-Newtonian viscosities. The rheology of a Newtonian surfactant is described as having a viscosity that is independent of the shear rate (i.e., the system will have the same viscosity as different levels of shear are applied). The rheology of a non-Newtonian surfactant system is described as having a viscosity that is dependent on the shear rate. For a non-Newtonian shear thinning surfactant system, viscosity will be reduced as shear rate is increased. This non-Newtonian rheological behavior effectively allows the suspension of undissolved solids, liquids and gases.

According to U.S. Patent No. 5,556,628, free flowing non-Newtonian shear thinning cosmetic preparations with good storage stability properties can be prepared utilizing specified surfactant mixtures comprised of an anionic surfactant, sodium lauryl ether sulfate (also known as sodium laureth sulfate) and identified co-surfactants and electrolytes. Experiments confirm that non-Newtonian shear thinning formulations can be prepared following the teachings of U.S. Patent No. 5,556,628. The subject formulations demonstrate good room temperature (25°C) and elevated temperature (45°C) viscosity stabilities.

However, such systems may not exhibit optimum performance under all conditions including, but not limited to, freeze/thaw conditions.

Other disclosures suggest the use of fatty acid structurants to stabilize lamellar phase systems (see e.g., U.S. Patent Nos. 6,150,312, 5,952,286 and 5,962,395). The inherent disadvantage of such systems requiring fatty acid ingredients is that fatty acids form insoluble salts (Ca⁺² and Mg⁺² salts) in hard water, which leave an undesirable residue on surfaces such as hair, skin, hard surfaces, etc. This residue is particularly unwanted in shampoo formulations where it will cause dulling of the hair and will act as a foam depressant that negatively impacts high foaming cosmetic formulations such as hair shampoos and body washes.

Moreover, it is difficult to maintain the stability and integrity of other known systems, particularly under freeze/thaw conditions.

Accordingly, it would be desirable to obtain a free flowing non-Newtonian shear thinning composition suitable for use in personal care compositions having the capacity to suspend water-insoluble particles and having stability under freeze/thaw conditions.

SUMMARY OF THE INVENTION

5

10

15

20

Stable, free flowing cosmetic formulations containing anionic surfactants, electrolytes and alkanolamides, which include long-chain aliphatic hydroxy (or polyhydroxy) amides (hereinafter referred to as long-chain aliphatic acid alkanolamides) or alkoxy long-chain aliphatic hydroxy (or polyhydroxy) amides (hereinafter referred to as alkoxy long-chain aliphatic acid alkanolamides), can be prepared which are ideally suited for the suspension of insoluble particles.

The compositions of the invention may be made by any suitable method for forming a free flowing composition. Electrolyte, surfactant and alkanolamide amounts may be variously adjusted to create a balance that yields the free flowing composition.

The compositions of the invention may be used to suspend agents useful in skin and hair care treatments including, but not limited to, UV absorbers, hair conditioning agents, hair and skin conditioning agents for use in 2 in 1 child care formulations that are tear free, skin conditioning agents, anti-bacterial agents, styling polymers for hair and skin care formulations (including rinse off applications such as shampoos), conditioning polymers for hair and skin care formulations, precipitated conditioning polymers for enhanced active delivery to hair and skin, conditioning polymers possessing high molecular weights and/or cationic charge densities for hair and skin care formulations, surfactants usually associated with solid formulations (such as cocoyl isethionates), and swellable polymers which hydrate only on application. The compositions of the invention may also be used in the preparation of stable, multi-phase personal care formulations, including those with colored stripes found in body washes, hair shampoos, skin cleansers, child care formulations, facial washes, and skin treatments.

DETAILED DESCRIPTION OF THE INVENTION

5

10

15

The invention relates to surfactant compositions which exhibit non-Newtonian shear
thinning behavior (herein referred to as free flowing compositions). These compositions
comprise water, at least one anionic surfactant, at least one electrolyte, and at least one
alkanolamide. The composition may further comprise water-insoluble particles or partially
insoluble components, and/or one or more additional surfactants taken from the categories of
anionic surfactants, nonionic surfactants, amphoteric and/or zwitterionic surfactants, and
cationic surfactants. The compositions of the present invention are stable compositions,

which can suspend difficult to incorporate components and are stable under freeze/thaw conditions.

Without wishing to be bound by theory, the inventors believe that in some examples the compositions of the invention may have a lamellar structure. The compositions of the invention have free-flowing non-Newtonian shear thinning properties and the ability to suspend components (which are known characteristics of lamellar phase surfactant compositions).

The anionic surfactant may be, for example, an aliphatic sulfonate, such as a primary alkane (e.g., C_8 - C_{22}) sulfonate, primary alkane (e.g., C_8 - C_{22}) disulfonate, C_8 - C_{22} alkene sulfonate, C_8 - C_{22} hydroxyalkane sulfonate or alkyl glyceryl ether sulfonate (AGS); an aromatic sulfonate such as alkyl benzene sulfonate, or a mixture thereof.

The anionic surfactant may also be an alkyl sulfate (e.g., C₁₂ -C₁₈ alkyl sulfate) or alkyl ether sulfate (including alkyl glyceryl ether sulfates). Preferred among the alkyl ether sulfates are those having the formula:

15
$$RO(CH_2 CH_2O)_n SO_3M$$
 (ii)

10

20

25

wherein R is an alkyl or alkenyl having 8 to 18 carbons, typically 12 to 18 carbons; n has an average value typically between 0 and 7, preferably between 0.5 and 3; and M is a solubilizing cation such as sodium, magnesium, potassium, ammonium or substituted ammonium. Lauryl and tridecyl R groups are preferable in some embodiments. The hydrophobic chain may be saturated or unsaturated, straight chain or branched.

The anionic surfactant may also be alkyl sulfosuccinates (including mono- and dialkyl, e.g., C_6 - C_{22} sulfosuccinates), alkyl and acyl taurates, alkyl and acyl sarcosinates, sulfoacetates, C_8 - C_{22} alkyl phosphates, alkyl phosphate esters, alkoxyl alkyl phosphate esters, acyl lactates, C_8 - C_{22} monoalkyl succinates and maleates, and acyl isethionates.

Sulfosuccinates may include monoalkyl sulfosuccinates having the formula:

(iii)

amido-MEA (monoethanolamide) sulfosuccinates of the formula

(iv)

wherein R₄ ranges from C₈ to C₂₂ alkyl and M is a solubilizing cation; and

5 amido-MIPA (monoisopropanolamide) sulfosuccinates of the formula

(v)

where M is as defined above for formula (ii) and R ranges from C₈ to C₂₂ alkyl.

Also included as anionic surfactants are the alkoxylated citrate sulfosuccinates and alkoxylated sulfosuccinates such as the following:

(vi)

where M is as defined above for formula (ii) and R ranges from C_{10} to C_{22} alkyl.

Sarcosinates are generally indicated by the formula

 $RCON(CH_3)CH_2\ CO_2\ M$, wherein R ranges from C_8 to C_{22} alkyl and M is a solubilizing cation.

Taurates are generally identified by the formula:

(vii)

wherein R_2 ranges from C_8 to C_{22} alkyl, R_3 ranges from C_1 to C_4 alkyl, and M is a solubilizing cation.

Another class of anionic surfactants are carboxylates of the following formula:

R-O-(CH₂CH₂O)_nCO₂M

25

(viii)

wherein R is C₈ to C₂₂ alkyl; n is 0 to 20; and M is as defined above in formula (ii). Other carboxylates which can be used include amido alkyl polypeptide carboxylates.

Other anionic surfactants which may be used are the C_8 - C_{22} acyl isethionates. These esters are prepared by reaction of alkali metal isethionate with mixed aliphatic fatty acids having from about 6 to about 22 carbon atoms and an iodine value of less than about 20. At

least about 75% of the mixed fatty acids have from about 12 to about 18 carbon atoms and up to about 25% have from about 6 to about 10 carbon atoms.

The acyl isethionate may be an alkoxylated isethionate such as is described in Ilardi et al., U.S. Pat. No. 5,393,466, hereby incorporated by reference to the extent it is consistent with this invention and application. This compound has the general formula:

5

15

20

25

wherein R is an alkyl group having 8 to 22 carbons, m is an integer from 1 to 4, X and Y are hydrogen or an alkyl group having 1 to 4 carbons, and M⁺ is a monovalent cation such as, for example, sodium, potassium or ammonium.

Anionic surfactants with branched alkyl chains such as sodium trideceth sulfate, for example, are preferred in some embodiments. Also, mixtures of anionic surfactants may be used in some embodiments.

The amount of anionic surfactant ingredient is typically about 5% to about 30%, and preferably about 10% to about 20% by weight of the composition.

Except in the examples or where otherwise explicitly indicated, all numbers in this disclosure indicating amounts or ratios of materials or conditions of reactions, physical properties of materials and/or use are understood to be modified by the word "about".

Where weight of a surfactant is utilized in this disclosure, weight is understood to mean weight of active surfactant, with the exception of the examples in the tables.

The electrolyte can be added separately to the composition or it can be included as part of one of the other raw materials. The electrolyte preferably includes an anion comprising phosphate, chloride, sulfate or citrate and a cation comprising sodium,

ammonium, potassium, magnesium or mixtures thereof. Some preferred electrolytes are sodium or ammonium chloride and sodium or ammonium sulfate.

The electrolyte should be present in an amount which facilitates formation of the free flowing composition. This amount will typically be from about 0.1% by weight to about 15% by weight, preferably from about 1% to about 6% by weight, but may be varied if required.

Typically, the composition comprises about 3% by weight to about 30% by weight of active surfactants. Frequently, surfactants are sold as solutions in water or other solvents which dilute them to less than 100% active surfactant, therefore the "active surfactant" means actual amount of surfactant delivered to the free flowing composition from a commercial surfactant preparation.

In some embodiments it is desirable that at least one of the components of the composition, such as the anionic surfactant, has an aliphatic chain that has branching or unsaturation or a combination thereof. Branching or branched means that at least one carbon atom of the aliphatic chain is joined to three or four other carbon atoms. Unsaturation means that at least two carbon atoms of the aliphatic chain are joined by a double bond.

The composition also includes at least one alkanolamide having the general structure of:

20
$$(R_1-O)_XH$$

 $R-C-N$
 $(R_2-O)_vH$

10

15

wherein R is C₈ to C₂₄, or preferably in some embodiments C₈ to C₂₂, or in other embodiments C₈ to C₁₈, saturated or unsaturated, straight chain or branched aliphatic groups,

 R_1 and R_2 are the same or different C_2 - C_4 straight chain or branched aliphatic groups, x = 0 to 10, y = 1 to 10, wherein the sum of x and y is less than or equal to 10.

That is, the alkanolamide preferably has a C₈ to C₂₄ aliphatic chain and the alkanolamide may include one to two alkanol groups which may either have a hydrocarbon backbone or an alkoxy backbone. The hydrocarbon alkanol groups may be C₂ to C₄ straight chain or branched aliphatic groups. The amount of alkanolamide in the composition is about 0.1% to about 10% by weight, and in some embodiments is preferably about 2% to about 5% by weight. Some preferred alkanolamides include cocamide MEA (coco monoethanolamide) and cocamide MIPA (coco monoisopropanolamide).

5

10

15

20

25

The term "alkanolamide" is used collectively hereinafter to include long chain aliphatic acid alkanolamides, alkoxy long-chain aliphatic acid alkanolamides, and mixtures thereof. Further, long-chain aliphatic acid alkanolamides may also be referred to in the art as fatty acid alkanolamides. Alkoxylated is taken to mean an alkanolamide derivitized with $(R_1 O)_x$ H wherein R_1 is a C_2 to C_4 straight chain or branched aliphatic group and x is 2 to 10. Examples of free flowing composition formulas are provided in Table 1 below. One advantage of this invention over the previously known formulations is that the composition formulas of the invention do not require a fatty acid structurant as a stabilizer, which in turn may negatively impact the performance of the products.

Additional surfactants from the classes of nonionic surfactants, amphoteric and/or zwitterionic surfactants, and cationic surfactants may optionally be incorporated so as to form a free flowing composition that is capable of suspending water-insoluble particles or partially insoluble components.

Amphoteric and/or zwitterionic surfactants that may be used in this invention preferably include at least one acid group, which may be a carboxylic or a sulphonic acid group. These surfactants include quaternary nitrogen and therefore are quaternary amido

acids. They generally include an alkyl or alkenyl group of 7 to 18 carbon atoms and usually comply with the overall structural formula:

O
$$R_2$$
| | | |
5 $R_1[C-NH(CH_2)_n]_m-N^+-X-Y$
| (x)

where R₁ is alkyl or alkenyl of 7 to 18 carbon atoms; R₂ and R₃ are each independently

hydrogen, alkyl, hydroxyalkyl or carboxyalkyl of 1 to 3 carbon atoms; n is 2 to 4; m is 0 to 1;

X is alkylene of 1 to 3 carbon atoms optionally substituted with hydroxyl; and Y is --CO₂ -
or --SO₃ --.

Suitable amphoteric and/or zwitterionic surfactants within the above general formula include simple betaines of formula:

15
$$R_2$$
 | $R_1-N^+-CH_2CO_2$ | R_3 (xi)

and amido betaines of formula:

$$\begin{array}{c} R_2 \\ | \\ R_1\text{-CONH(CH$_2$)_m-N^+-CH_2CO$^-$_2$} \\ 25 \qquad | \\ R_3 \qquad \qquad (xii) \end{array}$$

where m is 2 or 3.

In both formulae (xi) and (xii), R₁, R₂ and R₃ are as defined previously in connection

with formula (x). R₁ may in particular be a mixture of C₁₂ and C₁₄ alkyl groups derived from

coconut so that at least half, preferably at least three quarters, of the R₁ groups have 10 to 14 carbon atoms. R₂ and R₃ are preferably methyl.

A further possibility is that the amphoteric and/or zwitterionic detergent is a sulphobetaine of formula

where m is 2 or 3, or variants of these in which -- (CH₂)₃ SO₃ is replaced by

20

15

In these formulae (xiii), (xiv) and (xv), R_1 , R_2 and R_3 are as defined previously in connection with formula (x).

Amphoacetates and diamphoacetates may also be used. Amphoacetates generally conform to the following formula:

30

and diamphoacetates generally conform to the following formula:

(xvii)

5

10

15

20

25

where R is an aliphatic group of 8 to 18 carbon atoms and M is a cation such as sodium, potassium, ammonium, or substituted ammonium. Sodium lauroamphoacetate, sodium cocoamphoacetate, disodium lauroamphoacetate, and disodium cocoamphodiacetate are preferred in some embodiments.

The surfactant system or composition may also optionally include a nonionic surfactant. Nonionic surfactants which may be used include in particular the reaction products of compounds having a hydrophobic group and a reactive hydrogen atom, for example aliphatic alcohols, acids, amides and alkyl phenols, with alkylene oxides, especially ethylene oxide either alone or in combination with propylene oxide. Specific nonionic surfactant compounds include alkyl (C₆ -C₂₂) phenols-ethylene oxide condensates, the condensation products of aliphatic (C₈ -C₁₈) primary or secondary linear or branched alcohols with ethylene oxide, and products made by condensation of ethylene oxide with the reaction products of propylene oxide and ethylenediamine. Other so-called nonionic surfactant compounds include alkyl amine oxides, alkyl amido amine oxides, alkyl tertiary phosphine oxides, dialkyl sulphoxides, aliphatic fatty acid esters of C₈ -C₂₂ alcohols or ethoxylated alcohols, alkoxyl alkyl amines, sorbitan, sorbitan esters and sucrose esters.

The nonionic surfactant may also be a sugar amide, such as a polysaccharide amide. Specifically, the surfactant may be one of the lactobionamides described in U.S. Patent No. 5,389,279 or one of the sugar amides described in U.S. Patent No. 5,009,814, both of which are incorporated by reference herein to the extent that they are not inconsistent with this application.

Other surfactants which may be used are those described in U.S. Patent No. 3,723,325, and alkyl polysaccharide nonionic surfactants as disclosed in U.S. Patent No. 4,565,647, both of which are also incorporated by reference herein. Preferred alkyl polysaccharides are alkylpolyglycosides of the formula

5

10

20

25

$$R_2 O(C_n H_{2n} O)_t (glycosyl)_x$$
 (xvi)

wherein R₂ is selected from the group consisting of alkyl, alkylphenyl, hydroxyalkyl, hydroxyalkylphenyl, and mixtures thereof, in which the alkyl groups contain from about 10 to about 18, preferably from about 12 to about 14 carbon atoms; n is from 0 to about 3, preferably 2; t is from 0 to about 10, preferably 0; and x is from about 1.3 to about 10, preferably from about 1.3 to about 2.7. The glycosyl is preferably derived from glucose. To prepare these compounds, the alcohol or alkylpolyethoxy alcohol is formed first and then reacted with glucose, or a source of glucose, to form the glucoside (attachment at the 1-position). The additional glycosyl units can then be attached between their 1-position and the preceding glycosyl unit's 2-, 3-, 4- and/or 6-position, preferably the 2-position.

In some embodiments, the preferred nonionic surfactants include alkoxy fatty acid alcohols or alkypolyglycosides. The amphoteric and/or zwitterionic surfactants preferred in some embodiments include betaines, sultaines, amphoacetates, diamphoacetates or mixtures thereof. The total amount of active nonionic surfactants and amphoteric and/or zwitterionic surfactants is typically about 1% to about 20% and preferably about 3% to about 10% by weight.

The total amount of all surfactants, e.g. anionic surfactants, nonionic surfactants, amphoteric and/or zwitterionic surfactants, and cationic surfactants taken together is typically about 8% to about 30% active surfactant, and preferably about 10% to about 25% active

surfactant by weight. In some embodiments it is preferable that at least one of the surfactants has an aliphatic chain that has branching or unsaturation, or a combination thereof.

One embodiment of the invention relates to an aqueous free-flowing composition comprising (a) water, (b) at least one anionic surfactant including a hydrophobe comprised of linear or branched hydrophobic groups, (c) at least one electrolyte (which can either be separately added or included in one of the raw materials) and (d) at least one alkanolamide. The mixture may further comprise water-insoluble particles or partially insoluble components, and/or one or more additional surfactants from the categories of anionic, nonionic, amphoteric, zwitterionic and cationic, or a combination of these.

10

20

Surfactants (defined herein as generally referring to surface active agents, including all anionic, nonionic, amphoteric and/or zwitterionic and cationic surface active species and various mixtures thereof) are included in the composition in a combined amount such that the composition exhibits (i) non-Newtonian, shear thinning behavior, (ii) a viscosity equal to or greater than about 3,000 cps as measured at a spindle number 3, speed 6, with a Brookfield LVT viscometer at 25°C for 30 seconds, and (iii) said viscosity is stable under freeze/thaw conditions without requiring the addition of a separate freeze/thaw stabilizer. Stable is defined herein as a % drop of no more than 40%, preferably no more than 35%, in viscosity measured after at least 1 (one) freeze/thaw cycle, preferably at least 4 (four) freeze/thaw cycles. As used herein, one freeze/thaw cycle is a 24 hour period with 12 hours at -10°C and 12 hours at 25°C for the environment immediately surrounding the test sample. In some embodiments the composition may maintain water-insoluble particles or partially insoluble components in suspension.

The compositions of this invention are intended to include all formulations comprised of the surfactant system as described herein, an alkanolamide, an electrolyte, and water.

These compositions have free flowing properties capable of suspending a benefit agent(s) and are able to maintain stability under freeze/thaw conditions.

5

10

15

20

In some embodiments of the present invention it is desirable to include waterinsoluble particles or partially insoluble components in the free flowing composition. The terms "water-insoluble particles" and "partially insoluble components" mean solid or nonsolid entities which are not completely solubilized in the aqueous medium of the subject composition and include either insoluble or partially soluble species. The terms "waterinsoluble particles" and "partially insoluble components" are also understood to mean and encompass those situations where the solid or non-solid entities are present at concentrations above their solubility limit and therefore portions thereof remain undissolved. Typically, the water-insoluble particles or partially insoluble components can be solid particles, liquid ingredients, gases, or mixtures thereof. Some preferred examples of gases include air bubbles. Solid particles could include, for example, solid particles of zinc pyrethione, mica, alumina, silicon pigments, moisturizing beads, natural abrasives, synthetic abrasives (exfoliants) such as polyoxyethylene beads, and apricot seeds. The water-insoluble particles typically have an average particle size from about 0.5 to about 3,000 microns in diameter. The ability to suspend water-insoluble particles or partially soluble components is a desirable feature of the free-flowing non-Newtonian shear thinning liquid composition of the present invention.

Other examples of components that may be suspended by the compositions of the present invention are a number of benefit agents. A "benefit agent" means any active ingredient that is to be delivered into the skin or hair, or onto the skin or hair, or both, at a desired location. The suspended benefit agents may be present in an amount of from about 0 to about 35% by weight of the composition.

More particularly, the suspended benefit agents may include: vegetable oils, including arachis oil, castor oil, cocoa butter, coconut oil, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, sesame seed oil and soybean oil; esters, including butyl myristate, cetyl palmitate, decyloleate, glyceryl laurate, glyceryl ricinoleate, glyceryl stearate, glyceryl isostearate, hexyl laurate, isobutyl palmitate, isocetyl stearate, isopropyl isostearate, isopropyl laurate, isopropyl linoleate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, propylene glycol monolaurate, propylene glycol ricinoleate, propylene glycol stearate, and propylene glycol isostearate; animal fats, including acetylated lanolin alcohols, lanolin, lard, mink oil and tallow; and fatty acids and alcohols, including behenic acid, palmitic acid, stearic acid, behenyl alcohol, cetyl alcohol, eicosanyl alcohol and isocetyl alcohol.

10

15

20

25

Other examples of suitable benefit agents include: depigmentation agents; reflectants; UV absorbers, thickening agents; detangling/wet combing agents; film forming polymers; humectants; amino acids and their derivatives; antimicrobial agents; anti-acne agents; antiaging agents; antiseptics; analgesics; local anesthetics; anti-hair loss agents; hair growth inhibitor agents; inflammation inhibitors; proteins; deodorants and anti-perspirants; agents for treatment of dandruff, seborreheic dermatitis and psoriasis; skin emollients and skin moisturizers; hair conditioners; hair softeners; hair moisturizers; vitamins; tanning agents; skin lightening agents; antifungals such as antifungals for foot preparations; depilating agents; counterirritants; hemorrhoidals; insecticides; pigments or opacifying agents, moisturizing beads, natural abrasives, synthetic abrasives such as polyoxyethylene beads, mineral oils, petrolatum, silicone oils, polyalkylsiloxanes, polyalkyarylsiloxanes, sunscreens and the like; and mixtures thereof.

Examples of suitable reflectants include mica, alumina, calcium silicate, glycol dioleate, glycol distearate, silica, sodium magnesium fluorosilicate, and mixtures thereof.

Examples of suitable UV absorbers include benzophenone, bornelone, PABA (Para Amino Benzoic Acid), butyl PABA, cinnamidopropyl trimethyl ammonium chloride, disodium distyrylbiphenyl disulfonate, potassium methoxycinnamate, and mixtures thereof.

Commercially available thickening agents capable of imparting the appropriate viscosity to the compositions are suitable for use in this invention. Examples of suitable thickening agents include: mono or diesters of polyethylene glycol of the formula:

5

15

20

25

HO-(CH₂CH₂O)_zH (xvii)

10 wherein z is an integer from about 3 to about 200; fatty acids containing from about 16 to about 22 carbon atoms; fatty acid esters of alkoxy polyols; alkoxy derivatives of mono and diesters of fatty acids and glycerine; hydroxyalkyl cellulose; alkyl cellulose; hydroxyalkyl alkyl cellulose; and mixtures thereof. More specifically, suitable thickening agents nonexclusively include, for example, behenalkonium chloride, cetyl alcohol, quaternium 46, PG-hydroxyethyl cellulose, cocodimonium chloride, polyquaternium 6, polyquaternium 7, quaternium 18, PEG-18 glycerol oleate/cocoate, a mixture of acrylates/spirit 50 acrylate copolymer, laureth 3 and propylene glycol, a mixture of cocamidopropylbetaine and glyceryl laurate, a mixture of propylene glycol, PEG 55, and propylene glycol oleate, and mixtures thereof. Preferred thickeners include polyethylene glycol ester, and more preferably PEG-150 distearate.

Suitable detangling/wet combing agents include dioleovlamidoethyl hydroxythylmonium methosulfate, di (soyoylethyl) hydroxyethylmonium methosulfate, hydroxyethyl behenamidopropyl dimonium chloride, olealkonium chloride, polyquaternium 47, stearalkonium chloride, tricetylmonium chloride, guar hydroxypropyltrimonium chloride, hydroxypropyl guar hydroxypropyltrimonium chloride and mixtures thereof.

Suitable film forming polymers include those that, upon drying, produce a substantially continuous coating or film on the hair, skin, or nails. Examples of suitable film forming polymers include acrylamidopropyl trimonium chloride/acrylamide copolymer; corn starch/acrylamide/sodium acrylate copolymer; polyquaternium 10; polyquaternium 47; polyvinylmethyl/maleic anhydride copolymer; styrene/acrylates copolymers; and mixtures thereof.

Commercially available humectants which are capable of providing moisturization and conditioning properties to the composition are suitable for use in the present invention.

The humectant is preferably present in an amount of from about 0 percent to about 10 percent, more preferably from about 0.5 percent to about 5 percent, and most preferably from about 0.5 percent to about 3 percent, based on the overall weight of the composition.

Examples of suitable humectants include: water soluble liquid polyols such as glycerine, propylene glycol, hexylene glycol, butylene glycol, pentylene glycol, dipropylene glycol, and mixtures thereof; polyalkylene glycols of the formula:

15

10

$$HO-(R"O)_b-H$$
 (xviii)

wherein R" is an alkylene group having from about 2 to about 4 carbon atoms and b is an integer of from about 1 to about 10 (such as PEG 4); polyethylene glycol ethers of methyl glucose having the formula:

$$CH_3-C_6H_{10}O_5-(OCH_2CH_2)_c-OH$$
 (xix)

wherein c is an integer from about 5 to about 25; urea; fructose; glucose; honey; lactic acid; maltose; sodium glucuronate; and mixtures thereof. In a more preferred embodiment, the humectant is glycerine.

5

10

15

20

25

Suitable amino acids which may be beneficial to hair and skin and in some cases can be included as conditioning agents in the compositions of the present invention include amino acids derived from the hydrolysis of various proteins as well as the salts, esters, and acyl derivatives thereof. Examples of such amino acids nonexclusively include amphoteric and/or zwitterionic amino acids such as alkylamido alkylamines; stearyl acetyl glutamate; capryloyl silk amino acids; capryloyl collagen amino acids; capryloyl keratin amino acids; capryloyl pea amino acids; cocodimonium hydroxypropyl silk amino acids; corn gluten amino acids; cysteine; hair keratin amino acids; hair amino acids such as aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, half-cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, cysteic acid, lysine, histidine, arginine, cysteine, tryptophan, citrulline; other silk amino acids and wheat amino acids; and mixtures thereof.

Suitable proteins which may be beneficial to hair and skin and in some cases can be included as conditioning agents include those polymers that have a long chain, i.e. at least about 10 carbon atoms, and a high molecular weight, i.e. at least about 1000, and are formed by self-condensation of amino acids. Examples of such proteins include collagen, deoxyribonuclease, iodized corn protein, keratin, milk protein, protease, serum protein, silk, sweet almond protein, wheat germ protein, wheat protein, alpha and beta helix of keratin proteins, hair proteins such as intermediate filament proteins, high-sulfur proteins, ultrahigh-sulfur proteins, intermediate filament-associated proteins, high-tyrosine proteins, high-glycine tyrosine proteins, tricohyalin, and mixtures thereof.

Examples of suitable vitamins which may be beneficial to hair and skin and in some cases can be included as conditioning agents include vitamin B complex, including thiamine,

nicotinic acid, biotin, pantothenic acid, choline, riboflavin, vitamin B6, vitamin B12, pyridoxine, inositol, carnitine; vitamins A,C,D,E,K and their derivatives, such as vitamin A palmitate; and pro-vitamins, e.g., panthenol (pro vitamin B5), panthenol triacetate and mixtures thereof.

Examples of suitable antibacterial agents for hair and skin care applications include bacitracin, erythromycin, triclosan, neomycin, tetracycline, chlortetracycline, benzethonium chloride, phenol, parachlorometa xylenol (PCMX), triclocarban (TCC), chlorhexidine gluconate (CHG), zinc pyrithione, selenium sulfide and mixtures thereof.

5

10

15

20

Examples of suitable skin emollients and skin moisturizers include vegetable oils such as arachis oil, castor oil, cocoa butter, coconut oil, com oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, sesame seed oil and soybean oil; esters such as butyl myristate, cetyl palmitate, decyloleate, glyceryl laurate, glyceryl ricinoleate, glyceryl stearate, glyceryl isostearate, hexyl laurate, isobutyl palmitate, isocetyl stearate, isopropyl isostearate, isopropyl linoleate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, propylene glycol monolaurate, propylene glycol ricinoleate, propylene glycol stearate, and propylene glycol isostearate; animal fats such as acetylated lanolin alcohols, lanolin, lard, mink oil and tallow; fatty acids and alcohols of behenic acid, palmitic acid, stearic acid, behenyl alcohol, cetyl alcohol, eicosanyl alcohol and isocetyl alcohol.

Additional skin treatment agents and skin conditioning agents include salicylic acid, alpha hydroxy acids, vitamins, vitamin complexes, abrasives, silicones, silicone derivatives, polymers, natural oils, synthetic oils, mineral oils, lanolin, vegetable oils, isostearyl isostearate, glyceryl laurate, methyl gluceth 10, methyl gluceth 20, chitosan, and mixtures thereof.

Examples of suitable hair conditioners include silicones, silicone derivatives, natural oils, synthetic oils, nonionic surfactants, cationic surfactants, waxes, and polymers.

Quaternized compounds such as behenamidopropyl PG-dimonium chloride, tricetylammonium chloride, dihydrogenated tallowamidoethyl hydroxyethylmonium methosulfate, and mixtures thereof, as well as lipophilic compounds like cetyl alcohol, stearyl alcohol, hydrogenated polydecene, and mixtures thereof, may also be used.

5

10

15

20

25

Examples of suitable hair conditioning polymers include natural and/or synthetic cationic polymers, e.g. quaternized guar, quaternized cellulose, polyquaternium-7 and similar polymers typically at concentrations from about 0.1% to about 3.0% by weight of said composition; natural and/or synthetic nonionic polymers such as alkoxy or propoxylated guar or cellulose, alkyl guar or cellulose, polyethylene glycol, or a mixture of natural and synthetic nonionic polymers typically at concentrations from about 0.1% to about 3.0% by weight of said composition; and polyhydrol moisturizing agents, e.g. glycerine, propylene glycol, sorbitol and similar polymers. Preferable concentrations of polyhydrol moisturizing agents are typically in the range of about 0.2% to about 0.5% by weight of the composition.

Examples of suitable hair softeners include silicone compounds, such as those that are either non-volatile or volatile, or mixtures thereof, and those that are water soluble or water insoluble, or mixtures thereof. Examples of suitable silicones include organo-substituted polysiloxanes, which are either linear or cyclic polymers of silicone/oxygen monomers and which include cetyl dimethicone, cetyl triethylammonium dimethicone copolyol phthalate, cyclomethicone, dimethicone copolyol, dimethicone copolyol lactate, hydrolyzed soy protein/dimethicone copolyol acetate, silicone quaternium 13, stearalkonium dimethicone copolyol phthalate, stearamidopropyl dimethicone, and mixtures thereof.

Examples of suitable hair moisturizers include panthenyl ethyl ether, phytantriol, and mixtures thereof.

Examples of sunscreen agents include butyl methoxydibenzoylmethane, octyl methoxycinnamate, oxybenzone, octocrylene, octyl salicylate, phenylbenzimidazole sulfonic

acid, ethyl hydroxypropyl aminobenzoate, menthyl anthranilate, aminobenzoic acid, cinoxate, diethanolamine methoxycinnamate, glyceryl aminobenzoate, titanium dioxide, zinc oxide, oxybenzone, octyl dimethyl PABA (padimate O), red petrolatum, and mixtures thereof.

An example of a suitable tanning agent includes dihydroxyacetone.

Examples of skin lightening agents include hydroquinone, catechol and its derivatives, ascorbic acid and its derivatives, and mixtures thereof.

5

10

15

20

Examples of suitable insecticides, including insect repellents, anti-scabies and antilice treatments, are permethrin; pyrethrin; piperonyl butoxide; imidacloprid; N,N-diethyl toluamide, which refers to the material containing predominantly the meta isomer, i.e., N,Ndiethyl-m-toluamide, which is also known as DEET; compounds of the formula:

wherein R₅ is a branched or unbranched alkyl group having from about 1 to about 6 carbon atoms, R₆ is H, methyl or ethyl, R₇ is a branched or unbranched alkyl or alkoxy group having from about 1 to about 8 carbon atoms, and K is a -CN or a -COOR₈ group, wherein R₈ is a branched or unbranched alkyl group having from about 1 to about 6 carbon atoms; natural or synthetic pyrethroids, whereby the natural pyrethroids are contained in pyrethrum; the extract of the ground flowers of *Chrysanthemum cinerariaefolium* or *Chrysanthenum coccineum*; and mixtures thereof. Within the structure of Formula (xx) are ethyl 3-(N-butylacetamido) propionate, wherein R₇ is a CH₃ group, R₅ is an n-butyl group, R₆ is H, K is COOR₈ and R₈ is ethyl.

An example of an antifungal for foot preparations includes tolnaftate.

Examples of suitable depilating agents include calcium thioglycolate, magnesium thioglycolate, potassium thioglycolate, strontium thioglycolate, and mixtures thereof.

Examples of suitable external analgesics and local anesthetics include benzocaine, dibucaine, benzyl alcohol, camphor, capsaicin, capsicum, capsicum oleoresin, juniper tar, menthol, methyl nicotinate, methyl salicylate, phenol, resorcinol, turpentine oil, and mixtures thereof.

Examples of suitable antiperspirants and deodorants include aluminum chlorohydrates, aluminum zirconium chlorohydrates, and mixtures thereof.

5

10

15

20

25

Examples of suitable counterirritants include camphor, menthol, methyl salicylate, peppermint oils, clove oils, ichtammol, and mixtures thereof.

An example of a suitable inflammation inhibitor is hydrocortisone.

Examples of suitable hemorrhoidal products include anesthetics such as benzocaine, pramoxine hydrochloride, and mixtures thereof; antiseptics such as benzethonium chloride; astringents such as zinc oxide, bismuth subgallate, balsam Peru, and mixtures thereof; skin protectants such as cod liver oil, vegetable oil, and mixtures thereof.

Examples of suitable benefit agents having therapeutic components that are effective in the treatment of dandruff, seborrheic dermatitis, and psoriasis, as well as the symptoms associated therewith, include zinc pyrithione; shale oil and derivatives thereof such as sulfonated shale oil; selenium sulfide; sulfur; salicylic acid; coal tar; povidone-iodine; imidazoles such as ketoconazole, dichlorophenyl imidazolodioxalan, clotrimazole, itraconazole, miconazole, climbazole, tioconazole, sulconazole, butoconazole, fluconazole; miconazolenitrite and any possible stereo isomers and derivatives thereof such as anthralin; piroctone olamine (Octopirox); selenium sulfide; ciclopirox olamine; anti-psoriasis agents such as vitamin D analogs, e.g. calcipotriol, calcitriol, and tacaleitrol; vitamin A analogs such as esters of vitamin A including vitamin A palmitate, retinoids, retinols, and retinoic acid; corticosteroids such as hydrocortisone, clobetasone, butyrate, clobetasol propionate; and mixtures thereof.

Some preferred benefit agents for treatment of dandruff, seborrheic dermatitis, and psoriasis, as well as the symptoms associated therewith, include sulfonated shale oil, elubiol, 6-(1-piperidinyl)-2-4-pyrimidinediamine-3-oxide, finasteride, ketoconazole, salicylic acid, zinc pyrithione, coal tar, benzoyl peroxide, selenium sulfide, hydrocortisone, sulfur, menthol, praxomine hydrochloride, tricetylammonium chloride, polyquaternium 10, panthenol, panthenol triacetate, vitamin A and derivatives thereof, vitamin B and derivatives thereof, vitamin C and derivatives thereof, vitamin D and derivatives thereof, vitamin E and derivatives thereof, vitamin K and derivatives thereof, keratin, lysine, arginine, hydrolzed wheat proteins, hydrolyzed silk proteins, octyl methoxycinnamate, oxybenzone, minoxidil, titanium dioxide, zinc dioxide, retinol, erythromycin, tretinoin, and mixtures thereof.

Examples of benefit agents suitable for treating hair loss include, but are not limited to, potassium channel openers or peripheral vasodilators such as minoxidil, diazoxide, and compounds such as N"-cyano-N-(tert-pentyl)-N'-3-pyridinyl-guanidine ("P-1075") as disclosed in United States Patent No. 5,244,664, which is incorporated by reference herein; vitamins, such as vitamin E and vitamin C, and derivatives thereof such as vitamin E acetate and vitamin C palmitate; hormones such as erythropoietin; prostaglandins, such as prostaglandin EI and prostaglandin F2-alpha; fatty acids such as oleic acid; diuretics such as spironolactone; heat shock proteins ("HSP"), such as HSP 27 and HSP 72; calcium channel blockers, such as verapamil HCL, nifedipine, and diltiazemamiloride; immunosuppressant drugs, such as cyclosporin and Fk-506; 5 alpha-reductase inhibitors such as finasteride; growth factors such as EGF, IGF and FGF; transforming growth factor beta; tumor necrosis factor; non-steroidal anti-inflammatory agents such as benoxaprofen; retinoids and derivatives thereof such as tretinoin; cytokines, such as IL-6, IL-1 alpha, and IL-1 beta; cell adhesion molecules such as ICAM; glucocorticoids such as betamethasone; botanical extracts such as aloe, clove, ginseng, rehmannia, swertia, sweet orange, zanthoxylum, Serenoa repens

(saw palmetto), *Hypoxis rooperi*, stinging nettle, pumpkin seeds, and rye pollen; other botanical extracts including sandalwood, red beet root, chrysanthemum, rosemary, burdock root and other hair growth promoter activators as disclosed in DE 4330597, which is incorporated by reference herein to the extent that it is not inconsistent with the present application; homeopathic agents such as Kalium Phosphoricum D2, Azadirachta indica D2, and Joborandi DI; genes for cytokines, growth factors, and male-pattern baldness; antifungals such as ketoconazole and elubiol; antibiotics such as streptomycin; protein inhibitors such as cycloheximide; acetazolamide; benoxaprofen; cortisone; diltiazem; hexachlorobenzene; hydantoin; nifedipine; penicillamine; phenothiazines; pinacidil; psoralens; verapamil; zidovudine; alpha-glucosylated rutin having at least one rutin selected from quercetin, isoquercitrin, hesperidin, naringin, and methylhesperidin; and flavonoids and transglycosidated derivatives thereof which are all disclosed in JP 7002677, which is incorporated by reference herein to the extent that it is not inconsistent with the present application; and mixtures thereof.

Examples of benefit agents suitable for use in inhibiting hair growth include serine proteases such as trypsin; vitamins such as alpha-tocopherol (vitamin E) and derivatives thereof such as tocopherol acetate and tocopherol palmitate; antineoplastic agents, such as doxorubicin, cyclophosphamide, chlormethine, methotrexate, fluorouracil, vincristine, daunorubicin, bleomycin and hydroxycarbamide; anticoagulants, such as heparin, heparinoids, coumaerins, detran and indandiones; antithyroid drugs, such as iodine, thiouracils and carbimazole; lithium and lithium carbonate; interferons, such as interferon alpha, interferon alpha-2a and interferon alpha-2b; retinoids, such as retinol (vitamin A), isotretinoin; glucocorticoids such as betamethasone, and dexamethosone; antihyperlipidaemic drugs, such as triparanol and clofibrate; thallium; mercury; albendazole; allopurinol; amiodarone; amphetamines; androgens; bromocriptine; butyrophenones; carbamazepine;

cholestyramine; cimetidine; clofibrate; danazol; desipramine; dixyrazine; ethambutol; etionamide; fluoxetine; gentamicin; gold salts; hydantoins; ibuprofen; imipramine; immunoglobulins; indandiones; indomethacin; intraconazole; levadopa; maprotiline; methysergide; metoprolol; metyrapone; nadolol; nicotinic acid; potassium thiocyanate; propranolol; pyridostimine; salicylates; sulfasalazine; terfenadine; thiamphenicol; thiouracils; trimethadione; troparanol; valproic acid; and mixtures thereof.

5

10

15

20

25

Examples of suitable anti-aging agents include inorganic sunscreens such as titanium dioxide and zinc oxide; organic sunscreens such as octyl-methyl cinnamates and derivatives thereof; retinoids; vitamins such as vitamin E, vitamin A, vitamin C, vitamin B, and derivatives thereof such as vitamin E acetate, vitamin C palmitate, and the like; antioxidants including beta carotene, alpha hydroxy acid such as glycolic acid, citric acid, lactic acid, malic acid, mandelic acid, ascorbic acid, alpha-hydroxybutyric acid, alpha-hydroxyisobutyric acid, alpha-hydroxyisocaproic acid, atrolactic acid, alpha-hydroxyisovaleric acid, ethyl pyruvate, galacturonic acid, glucoheptonic acid, glucopheptono 1,4-lactone, gluconic acid, gluconolactone, glucuronic acid, glucuronolactone, glycolic acid, isopropyl pyruvate, methyl pyruvate, mucic acid, pyruvic acid, saccharic acid, saccharic acid 1,4-lactone, tartaric acid, and tartronic acid; beta hydroxy acids such as beta-hydroxybutyric acid, beta-phenyl-lactic acid, beta-phenylpyruvic acid; botanical extracts such as green tea, soy, milk thistle, algae, aloe, angelica, bitter orange, coffee, goldthread, grapefruit, hoellen, honeysuckle, Job's tears, lithospermum, mulberry, peony, puerarua, rice, safflower, and mixtures thereof.

Some preferred anti-aging agents comprise retinoids including retinol and tretinoin, anti-oxidants, alpha-hydroxy acids and beta-hydroxy acids.

Examples of suitable anti-acne agents include, but are not limited to, topical retinoids including tretinoin, isotretinoin, motretinide, adapalene, tazarotene, azelaic acid, retinol; salicylic acid; benzoyl peroxide; resorcinol; antibiotics such as tetracycline and isomers

thereof, erythromycin; anti-inflammatory agents such as ibuprofen, naproxen, hetprofen; botanical extracts such as alnus, amica, artemisia capillaris, asiasarum root, birth or afterbirth, calendula, chamomile, cnidium, comfrey, fennel, galla rhois, hawthron, houttuynia, hypericum, jujube, kiwi, licorice, magnolia, olive, peppermint, philodendron, salvia, sasa albomarginata; imidazoles such as ketoconazole and elubiol; those anti-acne agents described in Gollnick, H. et al. 196(I) Dermatology Sebaceous Glands, Acne and Related Disorders, 119-157 (1998), which is incorporated by reference herein to the extent that it is not inconsistent with the present application; and mixtures thereof.

Examples of suitable depigmentation agents include retinoids such as retinol; kojic acid and its derivatives such as, for example, kojic dipalmitate; hydroquinone and its derivatives such as arbutin; transexamic acid; vitamins such as niacin, vitamin C and its derivatives; azelaic acid; placertia; licorice; extracts such as chamomile and green tea; and mixtures thereof. Retinol, kojic acid, and hydroquinone are preferred.

10

20

25

Other examples of benefit agents include allergy inhibitors, anti-wrinkling agents, anti-pruritics, antitussives, hair growth promoting agents, antihistamines, anticholinergics, anti-emetics, antiinfectives, vasoconstrictors, vasodilators, wound healing promoters, peptides, polypeptides, medicament agents, shaving preparations, poison ivy products, poison oak products, burn products, anti-diaper rash agents, prickly heat agents, herbal extracts, retinal, flavoides, sensates, skin conditioners, hair lighteners, cell turnover enhancers and the like, and mixtures thereof.

Other components that may be added to the compositions include typical components added to personal care products, all of which are useful in enhancing the appearance or cosmetic properties of the product. These may include, for example, auxiliary thickeners such as carboxymethylcellulose, magnesium aluminum silicate, hydroxyethylcellulose, methylcellulose, carbopols, glucamides; sequestering agents such as tetrasodium

ethylenediaminetetraacetate (Na₄ - EDTA), EHDP or mixtures thereof, which can be present in varying amounts including amounts ranging from about 0.01 to about 5%, preferably about 0.01% to about 3%; and coloring agents, pigments, perfumes, opacifiers and pearlizers such as zinc stearate, magnesium stearate, TiO₂, EGMS (ethylene glycol monostearate) and Lytron 621 (Styrene/Acrylate copolymer).

5

10

15

20

Inclusion of antimicrobials may be used advantageously in some embodiments. Such antimicrobials include, for example, 2-hydroxy-4,2'4' trichlorodiphenylether (DP300); preservatives such as dimethyloldimethylhydantoin (Glydant XL1000), parabens, sorbic acid, etc.; antioxidants such as, for example, butylated hydroxytoluene (BHT), and mixtures thereof.

The compositions of the invention may be made by any suitable method for forming a free flowing composition. The amounts of electrolyte, surfactant, and alkanolamide may be variously adjusted to create a balance that yields the free flowing non-Newtonian shear thinning composition of the present invention.

The free-flowing non-Newtonian shear thinning compositions of the present invention may, in some embodiments, function as a delivery system. The amount of benefit agent to be combined with the composition of the invention may vary depending upon, for example, the resulting benefit desired and the sensitivity of the user to the benefit agent. Unless otherwise specified, typically the benefit agent is present in a personal care product in an amount, based upon the total weight of the free-flowing non-Newtonian shear thinning composition, from about 0.001% to about 20%. In a preferred embodiment, the benefit agent is present in an amount ranging from about 0.001% to about 10% of the composition, with a range from about 0.001% to about 5% being most preferred. While it is expected that one or more benefit agents may be used in a composition, the choice of benefit agent(s) to include will

depend upon the intended end use of the composition and the mutual compatibility of the benefit agents selected.

The compositions of the invention may also be used to prepare shampoos and conditioners, skin cleansing preparations, compositions for delivering cosmetic preparations or topical therapeutic agents, and the like.

5

10

20

The compositions of the invention may be used to suspend agents useful in skin and hair care treatments including, but not limited to, UV absorbers, hair conditioning agents, hair and skin conditioning agents for use in child care formulations including tear free shampoos and baby baths, skin conditioning agents, anti-bacterial agents, styling polymers for hair and skin care formulations (including rinse off applications such as shampoos), conditioning polymers for hair and skin care formulations, precipitated conditioning polymers for enhanced active delivery to hair and skin, conditioning polymers possessing high molecular weights and/or cationic charge densities for hair and skin care formulations, surfactants usually associated with solid formulations (such as cocoyl isethionates), and swellable polymers which hydrate only on application. The compositions of the invention may also be used in the preparation of stable, multi-phase personal care formulations, including those with colored stripes found in body washes, hair shampoos, skin cleansers, child care formulations including tear free shampoos, children's conditioning shampoos and baby baths, facial washes, and skin treatments.

In embodiments wherein the composition of the invention containing a benefit agent is used as a shampoo, the shampoo is applied to wet hair, then the hair is washed in accordance with known practices. More preferably, the composition remains on the hair from about 0 to about 10 minutes, and preferably from about 1 to about 5 minutes before rinsing.

The following nonlimiting examples are illustrative of the broad range of free-flowing non-Newtonian shear thinning compositions that may be prepared and used in accordance with the present invention.

EXAMPLE 1 Exemplary Compositions

5

15

Table 1 provides seven illustrative examples of compositions of the present invention (#1-7) having non-Newtonian shear thinning behaviors. It should be noted that the

10 percentages given without parentheses are amounts of commercial material added and the values in parentheses are the amounts of active ingredient added.

The compositions of Table 1 include illustrative examples in which oil, emollient or appearance modifiers have been included. These examples are provided as representative examples and are not intended to limit the inclusion of a particular additive to a particular composition nor to imply that only a single additive may be included. Indeed, inclusion of multiple kinds of water insoluble materials, particles, benefit agents, other optional ingredients, or mixtures thereof may be desirable in some embodiments.

TABLE I

		1	2	3	4	5	6	7
Empicol ESB-70 (Rhodia)	70% Active Sodium Laureth Sulfate	8.15 (5.70) ⁽¹⁾						
Rhodapex EST- 30 (Rhodia)	30% Active Sodium Trideceth Sulfate		48.50 (14.55)	48.50 (14.55)		47.4	53.2	53.2
Empicol BSD-52 (Albright & Wilson)	52% Active Sodium/ Magnesium Laureth Sulfate				28.30 (14.72)			
Empilan CIS (Albright & Wilson)	Cocamide MIPA	2.60		3.00	3.90			
Alkamide C-4 (Rhodia)	PEG-5 Cocamide					2.9		
Alkamide C-212 (Rhodia)	Cocamide MEA		3.00				5.0	5.0

		. 3,4.		3.	4	35	? 6	7
Miranol Ultra L-	32% Active		15.00	15.00		14.5		
32	Sodium		(4.8)	(4.8)	1			
(Rhodia)	Lauroamphoaceta			1	!			
	te		L		t			
Water	1					24.9	36.5	36.5
							1	
Empigen BB	Lauryl Betaine	0.70		T	13.00			
(Albright &		(0.21)			(3.9)	1		
Wilson)		()			(, ,			
Laureth-2		1.50	 		3.00	 	 	
								1
Glycerine			1.00	 	ł	-	 -	-
Jaguar C-17	Guar		0.50	0.50			1	1
(Rhodia)	Hydroxypropyltri		1			1		
····-	monium Chloride		1				1	
Sodium Chloride		12.40	3.00	3.00	16.20	8.6	5.0	5.0
Journal Cilional		(12.00)] 3.00	3.00	(15.55)	"."] 3.0	7.0
Citric Acid (to pH		(12.00)	Q.S.	Q.S.	1,5.55)	†	+	+
4.0-6.5)			٧٠٥.	٧٠٥.	1		1	
Citric Acid, 50%						1.7	0.3	0.3
Citne Acid, 50%					1	1.7	0.3	0.3
		l						
Sunflower Oil		 	6.67	+	 	 	 	
Petrolatum			3.33	1				
Silbione				3.00				
47V60,000		l	ľ					
TiO ₂		——	 	0.50	 	 	1	+
Mica		1.00	 	1			 	+
Lipo Pearl	Vera & Mineral	1		 	1.00		 	
Dipo i cari	Oil		İ	1	1.00			
Appearance		Opaque	White	White	Opaque	†	 	
Арреаганес		Liquid	Lotion	Lotion	Liquid			1
Sample		Liquid	Lotton	Louon	Liquid	24°C	23°C	23°C
Temperature for				1		240	1230	123 0
Viscosity	ļ						1	0
Initial Viscosity		7.7	152	120	16.7	8.5	10.7	10.3
(X1000) cPs		'.'	132	120	10.7	0.5	10.7	10.3
Viscosity after 4			 	 	ļ	0.6	+	
				1		8.5		1
days F/T				1			1	1
(X1000) cPs		ļ	<u> </u>	 		1	101	\ <u></u>
Viscosity after 5			1	l		1	9.6	9.7
days F/T				1			1	
(X1000) cPs			<u> </u>	1	<u> </u>		 	<u> </u>
Viscosity After		7.8	160	119	16.6			
F/T Cycle						1		
(X1000) cPs			l .	l	1	l	L	1

⁽¹⁾ values given in parentheses are amounts of active ingredient

EXAMPLE 2

Formulations and Testing of Alkoxy Alkanolamide Compositions

Alkoxy Alkanolamide (PEG-5 Cocamide, Alkamide ® C-4) was used to create a

structured liquid formulation with sodium trideceth sulfate, sodium lauroamphoacetate, and sodium chloride. The base formulation of this composition is provided in Table 2.

TABLE 2

Component	wt (g)	w/w%	% Act	
Rhodapex EST30	686	50.81	15.0	
Miranol Ultra L-32	210	15.56	4.9	
Alkamide C-4 (PEG-5 cocamide)	42	3.11	3.1	
Water	360.8	26.73		
50% Citric Acid	24.2	1.79		
Sodium Chloride	27	2.00		
	1350g	100.00%	23.0	pH = 6.08

A series of samples with various salt concentrations relative to the amount of base formulation of Table 2 were prepared and tested. The compositions of the tested samples are provided below in Table 3.

TABLE 3

Sample	% Rhodapex EST30	% Miranol Ultra L-32	% Alkamide C-4	% NaCl added	% water / inerts
8-1	50.8	15.6	3.1	2.0	28.5
8-2	50.3	15.4	3.1	3.0	28.2
8-3	49.8	15.2	3.0	4.0	28.0
8-4	49.3	15.1	3.0	4.9	27.7
8-5	48.8	14.9	3.0	5.9	27.4
8-6	48.3	14.9	3.0	6.8	27.1
8-7	47.8	14.6	2.9	7.7	26.9
8-8	47.4	14.5	2.9	8.6	26.6
8-9	46.9	14.4	2.9	9.5	26.3

Viscosities were measured for each of these exemplary compositions before and after 4 days of freeze/thaw. The viscosity was measured at LVT#3, 25°C, 6 RPM, 0.5 min.

Appearance was determined visually by observing the presence of air bubbles and sustaining the air bubbles in the suspended state before and after the freeze/thaw cycle. Only samples that were one phase in the initial centrifuge test were measured. The results, set forth below in Table 4, indicate that adding at least 8.5 % NaCl to the composition provided a stable formulation. As used herein, "structure" or "structured" means a system that appears shear thinning.

TABLE 4

Sample	Viscosity Before F/T	Viscosity After F/T	Appearance Structured?
8-4	4,680		No
8-5	7,760	•••	No
8-6	11,500	4,600	Yes
8-7	13,000	7,900	Yes
8-8	8,540	8,500	Yes
8-9	8,440	8,860	Yes

10

EXAMPLE 3

Formulations Without Amphoteric and/or Zwitterionic Surfactant

Compositions containing sodium trideceth sulfate, sodium chloride, and either

cocamide MEA or cocamide MIPA were tested for visual structured appearance and
freeze/thaw viscosity loss. An amphoteric surfactant was not used in these formulations. The
exemplary base formulations used for these compositions are provided in Tables 5 and 6
below.

TABLE 5

Base Formulation 9-1

Cocamide	MIPA	(Empilan	CIS)
----------	-------------	----------	------

Component	wt (g)	w/w%	% Act	
Rhodapex EST30	278.7	54.63	16.1	
Empilan CIS	26	5.10	5.1	
Water	191.3	37.49		
50% Citric Acid	1.70	0.33		
Sodium Chloride	12.5	2.45		
	510.2g	100.00%	21.2	pH = 5.4

5 <u>TABLE 6</u>

Base Formulation 9-2

Cocamide MEA (Alkamide C-212)

Component	wt (g)	w/w%	% Act	
Rhodapex EST30	278.7	54.63	16.1	
Alkamide C-212	26	5.10	5.1	
Water	191.3	37.50		
50% Citric Acid	1.64	0.32		
Sodium Chloride	12.5	2.45		
	510.14g	100.00%	21.2	pH = 5.6

A series of samples based upon each of the base formulations described above in

Tables 5 and 6, respectively, were prepared with various salt concentrations relative to the
amount of base formulation. Exemplary compositions were prepared, the formulations of
which are shown in Tables 7 and 8 below.

TABLE 7

Sample	% Rhodapex EST30	% Empilan CIS	% NaCl added	% water / inerts
9-1-1	54.6	5.1	2.5	37.8
9-1-2	53.8	5.0	4.0	37.2
9-1-3	53.2	5.0	5.0	36.8
9-1-4	52.7	4.9	5.9	36.5
9-1-5	52.1	4.9	6.9	36.1
9-1-6	51.6	4.8	7.8	35.8

TABLE 8

Sample	% Rhodapex	% Alkamide C-212	%	%
	EST30		NaCl added	water / inerts
9-2-1	54.6	5.1	2.5	37.8
9-2-2	53.8	5	4	37.2
9-2-3	53.2	5	5	36.8
9-2-4	52.7	4.9	5.9	36.5
9-2-5	52.1	4.9	6.9	36.1
9-2-6	51.6	4.8	7.8	35.8

The viscosity of these compositions before and after 5 days of freeze/thaw was measured in accordance with the procedures described above in Example 2. The results are set forth below in Table 9. As Table 9 shows, freeze/thaw viscosities and appearance data for the compositions of Tables 7 and 8 indicate that, for these compositions, a stable composition could be obtained with the addition of 5% or greater sodium chloride.

10 TABLE 9

5

Sample	Initial appearance	Initial Viscosity	F/T Viscosity	Appearance Structured?
9-1-1	25% clear			
9-1-2	1-phase	11,800	1,540	No
9-1-3	1-phase	10,280	9,700	Yes
9-1-4	1-phase	9,660	11,300	Yes
9-1-5	1-phase	9,480	11,760	Yes

Sample	Initial appearance	Initial Viscosity	F/T Viscosity	Appearance Structured?
9-1-6	1-phase	6,000	9,200	Yes
9-2-1	15% clear			•••
9-2-2	1-phase	13,360	3,000	No
9-2-3	1-phase	10,720	9,600	Yes
9-2-4	1-phase	9,460	11,900	Yes
9-2-5	1-phase	8,000	12,200	Yes
9-2-6	1-phase	2,300	10,400	Yes

EXAMPLE 4
Formulations and Testing of increasing levels of Alkanolamide

Alkamide ® C-212 (cocamide MEA) was used to create a structured liquid composition with sodium trideceth sulfate, sodium lauroamphoacetate, and sodium chloride.

The formulations of exemplary compositions are provided in Table 10 below.

TABLE 10

Sample	% Rhodapex	% Alkamide C-	% Miranol Ultra L-	% NaCl	% water	pH after
	EST30	212	32			citric acid
10-1	47.6	0	14.7	2.0	35.7	5.8
10-2	47.6	1.0	14.7	2.0	33.8	5.8
10-3	47.6	2.0	14.7	2.0	32.8	5.88
10-4	47.6	2.9	14.7	2.0	31.8	5.82
10-5	47.6	3.9	14.7	2.0	30.8	5.75
10-6	47.6	4.9	14.7	2.0	29.9	5.9
10-7	47.6	5.9	14.7	2.0	28.9	5.86

The viscosity was measured before and after one day of freeze/thaw in accordance with the procedures set forth in Example 2 and the results are summarized below in Table 11. As Table 11 shows, freeze/thaw viscosities (1 day) and appearance data for the compositions of Table 10 indicate that, for the examples tested, a stable composition could be obtained with 3% or greater added cocamide MEA.

TABLE 11

Sample	Viscosity Before F/T	Viscosity After F/T	Appearance
10-1	800	400	75% hazy
10-2	3,400	3,600	Hazy
10-3	3,800	4,100	Hazy
10-4	5,900	6,400	Incr. Opacity
10-5	7,500	7,100	Incr. Opacity
10-6	8,700	9,000	Incr. Opacity
10-7	11,000	11,500	Incr. Opacity

EXAMPLE 5 Preparation of Compositions

5

10

15

20

Methods for the preparation of compositions having non-Newtonian shear thinning behavior may be varied according to the physical features of a particular composition.

An exemplary method for preparing lower viscosity systems incorporating solid agents such as compositions 1 and 4 of Table 1 is as follows: all of the surface active agents (i.e. surfactants), including the alkanolamide, were added to the water with moderate agitation while stirring. When solid surfactants were used, the mixtures were heated to a minimum of about 5-10°C above the melting temperature of the solid surfactant. The mixtures were stirred until they become homogenous and, when heating was used, stirring was continued until the mixture cooled to ambient temperature. The pH was then adjusted to about 5.5 to 6.5 and the electrolyte and solid benefit agent were added with stirring to disperse.

An exemplary method for incorporating emollients into higher viscosity systems such as compositions 2 and 3 of the table set forth in Table 1 is as follows. Cationic polymer was first added to water. This was accomplished either by pre-solubilization of the cationic polymer in glycerine or adding the cationic polymer directly to the water and adjusting the pH to 4-5. Anionic surfactants, and any co-surfactants or ingredients (other than any

amphoteric and/or zwitterionic surfactants and alkanolamides) were added and the mixture was heated to about 65-80°C, e.g. a temperature greater than the melting point of the alkanolamide used. The alkanolamide was then added and the composition was mixed at a mixing speed of 200-400 RPM, utilizing an overhead mechanical stirrer with a stir shaft that includes (2) two impellers each with four pitched blades, the point of each blade being more strongly pitched than the center portion and the point of each blade alternating in an up and down pattern. A temperature at a minimum of 5-10°C above the melting point of the alkanolamide was maintained until the system was homogeneous. The emollient was heated to about 60-65°C and added to the surfactant mixture once the surfactant mixture reached approximately the same temperature, i.e., about 60-65°C. The mixture was then cooled to 30-35°C and the amphoteric and/or zwitterionic surfactant, if used, was added at the beginning of this cooling process. When a temperature of 30-35°C was reached, the pH was adjusted with citric acid, and heat sensitive additives such as color, fragrance, and preservatives, for example, as well as the electrolyte, were added. Mixing was continued for a minimum of 1-2 hours after the addition of electrolyte. A total 500g to 1000g was made per batch.

Those persons skilled in the art will appreciate that the present invention is susceptible to a broad utility and application. Many embodiments and adaptations of the invention, including various methods for preparing the composition of the present invention other than those herein described, as well as many variations and modifications, will be apparent from or reasonably suggested by the present invention and the foregoing description thereof, without departing from the substance or scope of the present invention. Accordingly, while the present invention has been described herein in detail in exemplary embodiments, it is to be understood that this disclosure is only illustrative and exemplary of the present invention and is made merely for purposes of providing a full and enabling disclosure of the invention. The foregoing is not intended or to be construed to limit the present invention or

otherwise to exclude any such other embodiments, adaptations, variations, modifications, the present invention being limited only by the claims appended hereto and the equivalents thereof.

WHAT IS CLAIMED IS:

1

2

1	1. Ar	aqueous free flowing composition comprising:
2	(a)	at least one anionic surfactant,
3	(b)	at least one alkanolamide;
4	(c)	at least one electrolyte; and
5	(d)	water,
6	wherein the a	at least one anionic surfactant, the at least one alkanolamide, and the at least one
7	electrolyte ar	e present in a combined amount such that the composition possesses non-
8	Newtonian sh	near thinning properties and a stable viscosity under at least one freeze/thaw
9	cycle.	
1	2. Th	e composition of Claim 1 further comprising at least one additional surfactant
2	selected from	the group consisting of nonionic, amphoteric, zwitterionic, and cationic
3	surfactants, o	r a combination thereof.
1	3. Th	e composition of Claim 1 further comprising at least one compound selected
2	from the grou	p consisting essentially of water-insoluble particles, partially insoluble
3	components,	and benefit agents.

flowing composition is equal to or greater than 3,000 cps.

4. The free flowing composition of Claim 1 wherein the initial viscosity of the free

5. The free flowing composition of Claim 1 wherein the free flowing composition is
 stable under at least three freeze/thaw cycles.

- 6. The free flowing composition of Claim 1 wherein the at least one anionic surfactant is selected from the group consisting of surfactants having a branched aliphatic chain, an unsaturated aliphatic chain, and combinations thereof.
- 7. The free flowing composition of Claim 1 wherein the anionic surfactant is sodium
 trideceth sulfate.
- 8. The free flowing composition of Claim 1 wherein the alkonolamide is selected from the group consisting of alkanolamides having a branched aliphatic chain, an unsaturated aliphatic chain, and combinations thereof.
- 9. The free flowing composition of Claim 1 wherein the alkanolamide is represented
 by the formula:

- wherein R is a C₈-C₂₄ saturated or unsaturated, straight chain or branched aliphatic group, R₁
 and R₂ are the same or different, C₂-C₄ straight chain or branched aliphatic groups, x = 0 to
 10, y = 1 to 10, and the sum of x and y is less than or equal to 10.
- 1 10. The free flowing composition of Claim 1 wherein the at least one additional surfactant comprises sodium lauroamphoacetate.

1 11. The composition of Claim 1 wherein the at least one anionic surfactant comprises

- 2 about 5% to about 30% by weight of the composition, the at least one alkanolamide
- 3 comprises about 0.1% to about 10% by weight of the composition, and the at least one
- 4 electrolyte comprises about 0.1% to about 15% by weight of the composition.
- 1 12. The composition of Claim 1 wherein the at least one anionic surfactant comprises
- 2 about 10% to about 20% by weight of the composition, the at least one alkanolamide
- 3 comprises about 2% to about 5% by weight of the composition, and the at least one
- 4 electrolyte comprises about 1% to about 6% by weight of the composition.
- 1 13. The composition of Claim 3 wherein the benefit agent is selected from the group
- 2 consisting of anti-dandruff agents, pigments or opacifying agents, moisturizing beads, natural
- 3 abrasives, synthetic abrasives such as polyoxyethylene beads, sunscreen agents, vegetable
- 4 oils, animal fats, mineral oils, petrolatum, silicone oils, polyalkylsiloxanes,
- 5 polyalkyarylsiloxanes, esters, fatty acids and alcohols, depigmentation agents, reflectants, UV
- 6 absorbers, thickening agents, detangling/wet combing agents, film forming polymers,
- 7 humectants, amino acids and their derivatives, antimicrobial agents, anti-acne agents, anti-
- 8 aging agents, antiseptics, analgesics, local anesthetics, anti-hair loss agents, hair growth
- 9 inhibitor agents, inflammation inhibitors, proteins, deodorants and anti-perspirants, agents for
- 10 treatment of dandruff, seborreheic dermatitis and psoriasis, skin emollients, skin moisturizers,
- 11 hair conditioners, hair softeners, hair moisturizers, vitamins, tanning agents, skin lightening
- 12 agents, antifungals, depilating agents, counterirritants, hemorrhoidals, insecticides,
- 13 sunscreens, and mixtures thereof.

1 14. The free flowing composition of Claim 13 wherein the anti-dandruff agent is 2 selected from the group consisting of zinc pyrithione and mica.

- 1 15. The free flowing composition of Claim 13 wherein the vegetable oil is selected 2 from the group consisting of arachis oil, castor oil, cocoa butter, coconut oil, corn oil, cotton 3 seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, sesame seed oil and 4 soybean oil.
- 1 16. The free flowing composition of Claim 13 wherein the ester is selected from the 2 group consisting of butyl myristate, cetyl palmitate, decyloleate, glyceryl laurate, glyceryl 3 ricinoleate, glyceryl stearate, glyceryl isostearate, hexyl laurate, isobutyl palmitate, isocetyl 4 stearate, isopropyl isostearate, isopropyl laurate, isopropyl linoleate, isopropyl myristate, 5 isopropyl palmitate, isopropyl stearate, propylene glycol monolaurate, propylene glycol 6 ricinoleate, propylene glycol stearate, and propylene glycol isostearate vegetable oil is 7 selected from the group consisting of arachis oil, castor oil, cocoa butter, coconut oil, corn 8 oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, sesame seed oil 9 and soybean oil.
- 1 17. The free flowing composition of Claim 13 wherein the animal fat is selected from 2 the group consisting of acetylated lanolin alcohols, lanolin, lard, mink oil and tallow.
- 1 18. The free flowing composition of Claim 13 wherein the fatty acid and alcohol is 2 selected from the group consisting of behenic acid, palmitic acid, stearic acid, behenyl 3 alcohol, cetyl alcohol, eicosanyl alcohol, isocetyl alcohol.

1 19. The composition of Claim 13 wherein the benefit agent is a UV absorber useful
2 in skin care applications to protect skin from UV light.

- 20. The composition of Claim 13 wherein the benefit agent is a UV absorber useful
 in hair care applications to protect hair from UV light.
- 21. The composition of Claim 13 wherein the benefit agent is a hair conditioning
 agent.
- 22. The composition of Claim 21 wherein the hair conditioning agent is selected from
 the group consisting of silicones, silicone derivatives, natural oils, nonionic surfactants,
 waxes, synthetic oils, cationic surfactants, and polymers.
- 23. The composition of Claim 13 wherein the benefit agent is selected from the group
 consisting of hair and skin conditioning agents for child care formulations.
- 24. The composition of Claim 23 wherein the benefit agent is selected from the group
 consisting of silicones, silicone derivatives, natural oils, nonionic surfactants, waxes,
 synthetic oils, cationic surfactants, and polymers.
- 25. The composition of Claim 23 wherein the child care formulation is selected from
 the group consisting of tear free shampoos, children's conditioning shampoos and baby baths.
- 26. The composition of Claim 13 wherein the benefit agent is selected from the group
 consisting of skin treatment agents and skin conditioning agents.

1 27. The composition of Claim 26 wherein the benefit agent is selected from the group 2 consisting of salicylic acid, alpha hydroxy acids, vitamins, vitamin complexes, abrasives, 3 silicones, silicone derivatives, natural oils, synthetic oils, and polymers. 28. The composition of Claim 13 wherein the benefit agent is selected from the group 1 2 consisting of anti-bacterial agents. 1 29. The composition of Claim 28 wherein the anti-bacterial agent is selected from the group consisting of triclosan, TCC, CHG, zinc pyrithione, PCMX, and selenium sulfide. 2 1 30. The composition of Claim 13 wherein the benefit agent comprises hair styling 2 polymers. 1 31. The composition of Claim 13 wherein the benefit agent is selected from the group 2 consisting of conditioning polymers possessing high molecular weights and conditioning 3 polymers possessing high cationic charge densities. 1 32. The composition of Claim 13 wherein the benefit agent comprises a precipitated 2 conditioning polymer. 1 33. The composition of Claim 13 wherein the benefit agent comprises a surfactant

2

usually associated with solid formulations.

34. The composition of Claim 33 wherein the surfactant comprises cocoyl
isethionate.

- 35. The composition of Claim 13 wherein the benefit agent comprises a swellable
 polymer that hydrates only on application.
- 36. A stable, multi phase personal care formulation comprising the composition of
 Claim 1.
- 1 37. The personal care formulation of Claim 36 wherein the personal care formulation
- 2 is selected from the group consisting of striped body washes, hair shampoos, skin cleansers,
- 3 child care formulations, facial washes, and skin treatments.
- 1 38. A method for making an aqueous free flowing composition comprising admixing:
- 2 (a) at least one anionic surfactant,
- 3 (b) at least one alkanolamide;
- 4 (c) at least one electrolyte; and
- 5 (d) water,
- 6 wherein the at least one anionic surfactant, the at least one alkanolamide, and the at least one
- 7 electrolyte are present in a combined amount such that the composition possesses non-
- 8 Newtonian shear thinning properties and a stable viscosity under at least one freeze/thaw
- 9 cycle.

39. The method of Claim 38 further comprising incorporating into the composition at 1 least one compound selected from the group consisting essentially of water-insoluble 2 3 particles, partially insoluble components, and benefit agents. 40. The method of Claim 39 wherein the at least one compound is a solid. 1 41. The method of Claim 39 wherein the at least one compound is a liquid. 1 1 42. The method of Claim 39 wherein the at least one compound is a gas. 43. An aqueous free flowing composition consisting essentially of: 1 2 at least one anionic surfactant, (a) 3 (b) at least one alkanolamide; 4 (c) at least one electrolyte; and 5 (d) water, wherein the at least one anionic surfactant, the at least one alkanolamide, and the at least one 6 7 electrolyte are present in a combined amount such that the composition possesses non-8 Newtonian shear thinning properties and a stable viscosity under at least one freeze/thaw 9 cycle. 1 44. The composition of Claim 43 further comprising at least one additional surfactant

selected from the group consisting of nonionic, amphoteric, zwitterionic, and cationic

2

3

surfactants, or a combination thereof.

45. The composition of Claim 43 further comprising at least one compound selected
 from the group consisting essentially of water-insoluble particles, partially insoluble
 components, and benefit agents.

- 1 46. The free flowing composition of Claim 43 wherein the initial viscosity of the free 2 flowing composition is equal to or greater than 3,000 cps.
- 47. The free flowing composition of Claim 43 wherein the free flowing composition
 is stable under at least three freeze/thaw cycles.
- 48. The free flowing composition of Claim 43 wherein the at least one anionic
 surfactant is selected from the group consisting of surfactants having a branched aliphatic
 chain, an unsaturated aliphatic chain, and combinations thereof.
- 49. The free flowing composition of Claim 43 wherein the alkonolamide is selected
 from the group consisting of alkanolamides having a branched aliphatic chain, an unsaturated
 aliphatic chain, and combinations thereof.
- 50. The composition of Claim 43 wherein the at least one anionic surfactant
 comprises about 5% to about 30% by weight of the composition, the at least one
 alkanolamide comprises about 0.1% to about 10% by weight of the composition, and the at
 least one electrolyte comprises about 0.1% to about 15% by weight of the composition.
- 1 51. The composition of Claim 43 wherein the at least one anionic surfactant 2 comprises about 10% to about 20% by weight of the composition, the at least one

3 alkanolamide comprises about 2% to about 5% by weight of the composition, and the at least

- 4 one electrolyte comprises about 1% to about 6% by weight of the composition.
- 1 52. The composition of Claim 45 wherein the benefit agent is selected from the group
- 2 consisting of anti-dandruff agents, pigments or opacifying agents, moisturizing beads, natural
- 3 abrasives, synthetic abrasives such as polyoxyethylene beads, sunscreen agents, vegetable
- 4 oils, animal fats, mineral oils, petrolatum, silicone oils, polyalkylsiloxanes,
- 5 polyalkyarylsiloxanes, esters, fatty acids and alcohols, depigmentation agents, reflectants, UV
- 6 absorbers, thickening agents, detangling/wet combing agents, film forming polymers,
- 7 humectants, amino acids and their derivatives, antimicrobial agents, anti-acne agents, anti-
- 8 aging agents, antiseptics, analgesics, local anesthetics, anti-hair loss agents, hair growth
- 9 inhibitor agents, inflammation inhibitors, proteins, deodorants and anti-perspirants, agents for
- 10 treatment of dandruff, seborreheic dermatitis and psoriasis, skin emollients, skin moisturizers,
- 11 hair conditioners, hair softeners, hair moisturizers, vitamins, tanning agents, skin lightening
- 12 agents, antifungals, depilating agents, counterirritants, hemorrhoidals, insecticides,
- 13 sunscreens, and mixtures thereof.

PCT/US 02/41126

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K7/075 A61K A61K7/42 A61K7/48 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO OO 76460 A (HATCHMAN KEVAN ; RHODIA CONS 1-52 SPEC LTD (GB); LUKENBACH ELVIN (US); M) 21 December 2000 (2000-12-21) page 4, line 1 -page 6, line 3 page 12 -page 25 X WO 01 96461 A (CHESHAM CHEMICALS LTD 1-52 ;HICKEY MARTINA (GB); MITCHELL DAVID (GB); W) 20 December 2001 (2001-12-20) formulation examples US 5 910 302 A (HERTER PATRICIA D ET AL) 1-52 X 8 June 1999 (1999-06-08) table 1 -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance Invention "E" earlier document but published on or after the International "X" document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to fillng date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-*O* document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. document published prior to the international filing date but later than the priority date claimed *&* document member of the same patent family Date of the actual completion of the International search Date of mailing of the International search report 6 May 2003 14/05/2003 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Lindner, A

Fax: (+31-70) 340-3016

PCT/US 02/41126

		PC1/US UZ/41126
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	185
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 312 234 A (PROCTER & GAMBLE) 19 April 1989 (1989-04-19) table claims 1-6	1-52
X	EP 0 569 028 A (LONZA AG) 10 November 1993 (1993-11-10) claims 1-8; examples 5,6	1-52
X	EP 0 968 706 A (LILLY CO ELI) 5 January 2000 (2000-01-05) examples 4-6	1-52
X	US 5 997 854 A (VON MALLEK PETER) 7 December 1999 (1999-12-07) claims 1-42	1-52
X	US 4 933 176 A (VAN REETH ISABELLE M E) 12 June 1990 (1990-06-12) examples 1,4,12	1-52
X	US 5 292 504 A (CARDIN CAROLINE W ET AL) 8 March 1994 (1994-03-08) claims 1-8; examples 4-6	1-52
		-

PCT/US 02/41126

Patent document dited in search report		Publication date		Patent family member(s)	Publication date
WO 0076460	A	21-12-2000	AU	5971600 A	02-01-2001
no 00/0700	~	-1 IL 2000	WO	0076460 A2	21-12-2000
			EP	1207839 A2	29-05-2002
			US	2002034489 A1	21-03-2002
WO 0196461	Α	20-12-2001	GB	2363386 A	19-12-2001
			AU	7422901 A	24-12-2001
			EP	1294802 A1	26-03-2003
			WO	0196461 A1	20-12-2001
US 5910302	Α	08-06-1999	US	5879671 A	09-03-1999
EP 0312234	Α	19-04-1989	AU	2390888 A	01-06-1989
			CA	1328814 A1	26-04-1994
			CN	1032488 A	26-04-1989
			DK	572588 A	17-04-1989
			EG	18594 A	30-08-1993
			ĒΡ	0312234 A2	19-04-1989
			FΙ	884750 A	17-04-1989
			JP	2111713 A	24-04-1990
			NZ	226572 A	25-06-1991
			PH	26997 A	01-02-1993
EP 0569028	Α	10-11-1993	CA	2095743 A1	08-11-1993
LI 0303020	А	10 11 1990	EP	0569028 A2	10-11-1993
			ŪS	5478490 A	26-12-1995
EP 0968706	Α	05-01-2000	AU	750046 B2	11-07-2002
L: 0300/00	^	00 01 2000	AU	4700499 A	24-01-2000
			BR	9911795 A	27-03-2001
			CA	2337789 A1	13-01-2000
			CN	1314812 T	26-09-2001
			CZ	20004865 A3	16-01-2002
			EA	3060 B1	26-12-2002
			EP	0968706 A2	05-01-2000
			HR	20000918 A1	31-10-2001
			HU	0102482 A2	28-11-2001
				2002519365 T	02-07-2002
			JP NO	2002519365 T 20010014 A	28-02-2001
			NO NZ	509118 A	28-02-2001 28-02-2003
			PL	348306 A1	20-05-2002
			SK	20062000 A3	20-05-2002 05-02-2002
			TR	20002000 A3 200003818 T2	21-06-2001
			WO	0001347 A2	13-01-2000
			US	6063771 A	16-05-2000
			US	6342482 B1	29-01-2002
US 5997854	A	07-12-1999	AU	5453098 A	03-07-1998
			MO	9825579 A1	18-06-1998
			US	5888489 A	30-03-1999
US 4933176	Α	12-06-1990	CA	1329552 A1	17-05-1994
			DE	3911177 A1	19-10-1989
			FR	2629714 A1	13-10-1989
			GB	2217342 A ,B	25-10-1989
			IT	1232848 B	05-03-1992
-			JP	1305019 A	08-12-1989
					

PCT/US 02/41126

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5292504	Α	08-03-1994	AT	155642 T	15-08-1997
*** ****			AU	7656891 A	11-11-1991
			CN	1056618 A	04-12-1991
			DE	69126969 D1	04-09-1997
			DE	69126969 T2	05-03-1998
			DK	525078 T3	25-08-1997
			EP	0525078 A1	03-02-1993
			ES	2106779 T3	16-11-1997
			FI	924669 A	15-10-1992
			GR	3024821 T3	30-01-1998
			ΙE	911282 A1	23-10-1991
			MX	173195 B	07-02-1994
			NZ	237853 A	25-06-1992
			PT	97405 A .B	31-01-1992
			WO	9115953 A1	31-10-1991